Dr. Reddy’s Laboratories has launched Colesevelam HCI Tablets, USP, a therapeutic equivalent generic version of WELCHOL (colesevelam HCI) Tablets in the United States market approved by the US Food and Drug Administration (USFDA).
The WELCHOL brand and generic had US sales of around $471 million MAT for the most recent twelve months ending in August 2018 according to IMS Health. Dr. Reddy’s Colesevelam Hydrochloride Tablets is available in 625 mg with 180 count bottle size.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.